Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Open Access
- 7 July 2025
- journal article
- immune cell-therapies-and-immune-cell-engineering
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (7) , e011330
Abstract
Background: Rhabdomyosarcoma (RMS) is the most common type of soft-tissue sarcoma in children, and it remains a challenging cancer with poor outcomes in high-risk and metastatic patients. This study reports the use of epidermal growth factor receptor (EGFR)-targeted chimeric antigen receptor (CAR) natural killer (NK) cells in combination with radiotherapy as a novel immunotherapeutic approach for RMS treatment. Methods: Primary human NK cells from healthy donors were engineered using lentiviral transduction to express a cetuximab-based EGFR-specific CAR. The ability of the engineered NK cells to lyse RMS cells was then assessed in vitro in RMS monolayers and spheroids, as well as against chemotherapy-resistant and primary patient-derived RMS cells. Migratory properties of NK cells were observed in a subcutaneous RMS xenograft model using in vivo imaging, and the efficacy of EGFR-CAR NK cells in combination with localized fractionated radiotherapy was analyzed. Results: Primary human EGFR-CAR NK cells demonstrated enhanced cytotoxicity against multiple RMS cell lines in both two-dimensional culture and three-dimensional spheroid models. Furthermore, EGFR-CAR NK cells were highly efficient against chemotherapy-resistant RMS cells and patient-derived samples. Importantly, EGFR-CAR NK cells also exhibited improved tumor homing compared with non-transduced NK cells in an in vivo RMS xenograft model. Notably, the combination of EGFR-CAR NK cell therapy with fractionated radiotherapy further enhanced NK cell infiltration into the tumor and reduced tumor growth. Conclusion: This study provides a proof-of-concept for EGFR-CAR NK cells as a promising immunotherapy for RMS, particularly when combined with radiotherapy to overcome barriers of solid tumors. This combinatorial approach may hold potential to improve outcomes for patients with RMS and other EGFR-expressing malignancies.Keywords
Funding Information
- Deutsche Krebshilfe (70113301, 70115200)
- Hessisches Ministerium für Wissenschaft und Kunst (519/03/03.001)
- Deutsche Kinderkrebsstiftung (DKS_A2023_01)
- Deutsche Forschungsgemeinschaft (318346496, 493624332)
- Menschen für Kinder e.V. (N/A)
This publication has 54 references indexed in Scilit:
- Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomasPediatric Blood & Cancer, 2012
- Shaping of NK Cell Responses by the Tumor MicroenvironmentCancer Microenvironment, 2012
- Monocyte Chemoattractant Protein-1 Secreted by Decidual Stromal Cells Inhibits NK Cells Cytotoxicity by Up-Regulating Expression of SOCS3PLOS ONE, 2012
- Randomized Comparison of Intensified Six-Drug Versus Standard Three-Drug Chemotherapy for High-Risk Nonmetastatic Rhabdomyosarcoma and Other Chemotherapy-Sensitive Childhood Soft Tissue Sarcomas: Long-Term Results From the International Society of Pediatric Oncology MMT95 StudyJournal of Clinical Oncology, 2012
- Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcomaLaboratory Investigation, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma CellsJournal of Immunotherapy, 2002
- Unique Subpopulations of CD56+ NK and NK-T Peripheral Blood Lymphocytes Identified by Chemokine Receptor Expression RepertoireThe Journal of Immunology, 2001
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001
- EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteinsInternational Journal of Cancer, 1995